Introduction
============

*Acinetobacter baumannii* is a non-fermentative, gram-negative opportunistic pathogen that can cause hospital-acquired pneumonia (HAP), blood infections and urinary tract infection, among others ([@B42]). The rapid spread ofthe multi-drug-resistant *A. baumannii* has resulted in very limited therapeutic options in the clinic. Sulbactam, a β-lactamase inhibitor, has intrinsic antimicrobial effects against *A. baumannii* by binding to penicillin-binding protein 2 ([@B40]). It is commercially available in a combined formulation of ampicillin and cefoperazone. The clinical efficacy of cefoperazone/sulbactam has been shown in previous work ([@B59]; [@B48]; [@B58]). This combination has recently been applied to treat critically ill patients receiving continuous venovenous hemofiltration, and 11 of 14 patients survived ([@B17]). This combination was also administrated to treat neurosurgical patients in a pilot study, with the results showing that cerebrospinal fluid penetration of cefoperazone/sulbactam could be enhanced after neurosurgical impairment of the blood-brain barrier ([@B55]). In a retrospective review of the outcomes for patients with cefoperazone/sulbactam treated *A. baumannii* bacteremia, 77% of the patients (27/35) presented successful clinical efficacy ([@B12]). Because the combination has been widely used in the clinic, the resistance rate was monitored and observed to increase from 25.0 to 37.7% from 2004 to 2010 in China ([@B23]). However, the underlying mechanism is not well understood *in vitro* or *in vivo*, for sulbactam alone or the combination. Sulbactam alone has been reported to cause resistance in *A. baumannii* via PBP3 mutation *in vitro*, despite a lack of information regarding natural pbp3 mutations in clinical isolates ([@B41]). The detection and expression of *bla*~TEM-1~ has been suggested to relate to the minimum inhibitory concentration (MIC) of sulbactam in *A. baumannii* ([@B54]). The combination resistance in *Klebsiella pneumoniae* in an *in vitro* study was reported owing to two different mechanisms, loss of a 39-kDa outer membrane protein and presence of TEM-2 β-lactamase ([@B45]).

Whole-genome sequencing is powerful and can reveal a vast amount of DNA information from a global perspective. The published complete genome sequences for many bacteria are beneficial and efficient for strain-to-reference sequencing and bioinformatics analysis ([@B32]). They can be used to identify resistance genes as well as minor changes in the genome due to mutation, gene transfer, gene duplication, and amplification. It has been seen as a basis for whole-genome sequencing revealing the mechanism of bacterial pathogen resistance that develops in patients ([@B49]; [@B56]; [@B21]). [@B57] sequenced 136 strains of *A. baumannii* isolated from patients and showed the genome changes occurred mainly due to the single nucleotide variance in protein coding regions and IS element. Genome sequenced *A. baumannii* showed the colistin resistance was due to the mutations in transcriptional regulatory genes ([@B10]). Susceptible *S. aureus* evolved resistance via a 35-point mutation in 31 loci in a patient with a bloodstream infection receiving vancomycin therapy ([@B38]). Tigecycline resistance to *A. baumannii* has been reported to be due to the deletion of three contigs *in vivo* ([@B22]). Additionally, gene amplification was frequently detected due to the antibiotic pressure. The evolution of β-lactamase resistance was studied by exposing *Salmonella typhimurium*, which contain low level β-lactamase resistance, in an environment of progressively increasing concentrations of cephalosporin. The results showed an amplification of *bla*~TEM-1~ gene copy number followed by acquisition of gene mutations ([@B51]). A genome-wide assay of *E. coli* strain in 78 different antibiotic environments found that 56 genes were amplified to fit the environment and reproducible increasing in MIC for their corresponding antibiotics was detected ([@B50]). The amplification of aminoglycoside resistance gene *aphA1* in *A. baumannii* has been considered to be the mechanism underlying the development of tobramycin *in vivo* ([@B34]).

In the present study, two *A. baumannii* isolates, AB1845 and AB2092, were collected before and after cefoperazone/sulbactam therapy from a patient with HAP. Pharmacokinetics/pharmacodynamics (PK/PD) was applied to evaluate the dosage regimen and development of resistance. Moreover, whole-genome sequencing was employed to investigate the mechanism of cefoperazone/sulbactam resistance of the two isolates developed *in vivo*.

Materials and Methods {#s1}
=====================

Medical Records and Treatment
-----------------------------

This study was approved by the institutional review board of Huashan Hospital affiliated to Fudan University. Written informed consent was obtained from the patient. A 19-year-old male patient with serious brain trauma was admitted to Huashan Hospital (Shanghai, China). The patient had a high fever with white blood cell counts out of the normal range after being checked into bed for 48 h. Both chest X-Ray radiophotography and computed tomography showed pneumonia. *A. baumannii* (AB1845) was isolated from the sputum of the patient, revealing bacterial infection. Hence, the patient was treated with meropenem 0.5 g q8h without clinical efficacy. On day 6, the dosage regimen was changed to cefoperazone/sulbactam (2:1, 3 g every 8 h with a 1-h infusion, SULPERAZON^®^, batch no. 95839116) for 20 days. The treatment was stopped when body temperature and white blood cell counts returned to the normal range; additionally, *A. baumannii* was not detected in the sputum. However, the patient had a fever, and *A. baumannii* (AB2092) was again isolated 4 days after cefoperazone/sulbactam treatment. The cefoperazone/sulbactam treatment was finally considered to have failed both clinically and microbiologically efficacy.

Pharmacokinetics of Cefoperazone/Sulbactam Treatment
----------------------------------------------------

Blood samples were collected before the first infusion, immediately after the infusion (0 h), and at 0.5, 1, 2, 4, 6 h afterward on day 4 (i.e., steady state) of the cefoperazone/sulbactam treatment. The drug concentration was determined using the LC-MS/MS method ([@B62]), which was validated according to the CFDA guidelines on bioanalytical method validation. The pharmacokinetic parameters of the patients were calculated by Winnonlin (v6.0, phoenix). The patient's pharmacokinetic profiles of cefoperazone and sulbactam were fit into a well-developed population PK model ([@B11]). The PK/PD indice of cefoperazone and sulbactam was %T~\>MIC~, namely the percentage of the dosing interval for which the plasma concentration of cefoperazone or sulbactam above the MIC. It was calculated based on the drug pharmacokinetic profile and MICs of the combination ([@B30]).

Bacterial Isolates and Susceptibility Testing
---------------------------------------------

*Acinetobacter baumannii* AB1845 and AB2092 were isolated from the sputum of the patient before and after cefoperazone/sulbactam therapy. Both isolates were stored at -80°C. The MIC was determined in cation-adjusted Mueller-Hinton broth (Becton-Dickinson, Sparks, MD, USA) using a broth microdilution according to Clinical and Laboratory Standards Institute (CLSI) standards. The MICs of the β-lactam/β-lactamase inhibitor combination, including cefoperazone/sulbactam, carbapenems, colistin, and polymyxin B, were determined.

Genome Sequencing and Analysis
------------------------------

Genomic DNA was extracted using a Genomic DNA Purification Kit (Tiangen, Beijing, China) according to the instruction manual and stored at -80°C before sequencing. A 300-bp paired-end library was constructed for the purified DNA sample following the standard Illumina paired-end protocol. Cluster generation was performed in C-bot, and sequencing was performed on the Illumina Hiseq2500 with 150 cycles. The sequence reads were cleaned using the FASTX toolkit^[1](#fn01){ref-type="fn"}^. Genome assembly was performed using Velvet (Ver 1.0.15) ([@B60]). Putative protein-coding sequences were determined by combining the prediction results of the glimmer 3.02 ([@B15]) and Z-Curve ([@B19]) program. The phylogenetic tree was constructed using PHYML ([@B18]) by concatenating orthologs based on the protein sequences in the published genome. Functional annotation of CDS was performed by searching the NCBI non-redundant protein database and the KEGG protein database ([@B27]). Gene annotation was mapped to the *A. baumannii* MDR-ZJ06 genome (from the phylogenetic tree) using Bowtie2 with default settings ([@B28]). Single Nucleotide Polymorphisms (SNPs) from alignments were called using Samtools-0.1.16 ([@B29]), and the output was generated in the pileup format. Gene amplification was detected by comparing the coverage of the reads in AB1845 and Ab2092 using the read depth method ([@B43]).

Quantitative Real-Time PCR Analysis of *bla*~OXA-23~
----------------------------------------------------

The mRNA expression level of *bla*~OXA-23~ was quantified by real-time PCR. AB1845 and AB2092 were cultured in cation-adjusted Mueller-Hinton broth and collected during the early log phase. Total RNA was extracted using a TaKaRa Mini BEST Universal RNA Extraction Kit (TaKaRa Biotechnology, Dalian, China) according to the manufacturer's instruction. Quantitative real-time PCR (qPCR) was performed using a two-step process. RNA was first reverse-transcribed to cDNA (TaKaRa Biotechnology, Dalian, China), and real-time PCR was conducted on an ABI Vii7 (Applied Biosystems, Carlsbad, CA, USA) using a TaKaRa SYBR^®^ FAST qPCR Kit with 40 cycles of denaturation for 5 s at 95°C, annealing for 30 s at 50°C, and extension for 20 s at 72°C. The PCR primers for the *bla*~OXA-23~ gene were F: CCGAGTCAGATTGTTCAAGGA and R: TGTAGAGGCTGGCACATATTC; and those for 16S rRNA were F: GGCGGCTTATTAAGTCGGATG and R: TTCGTACCTCAGCGTCAGTATT. The melting curve analysis was performed immediately after amplification to verify the specificity of the PCR amplification products.

Fluorescence was measured at the end of the annealing-extension phase of each cycle. A threshold value for the fluorescence of all samples was set manually. The reaction cycle at which the PCR product exceeded this fluorescence threshold was identified as the threshold cycle (CT). The relative quantitation was calculated by the 2-^ΔΔCT^ method ([@B47]). The student *t*-test was applied to evaluate the significance of the gene expression level of the two isolates.

Results
=======

Antibiotic Susceptibility
-------------------------

Minimum inhibitory concentrations were obtained for cefoperazone/sulbactam combinations, carbapenems, colistin and polymyxin B for the pre-therapy isolate AB1845 and the post-therapy isolate AB2092 (**Table [1](#T1){ref-type="table"}**). The MICs of the cefoperazone/sulbactam combination were 16/8 mg/L for AB1845; and the MICs of mono cefoperazone and sulbactam were \>128 mg/L and 32 mg/L. The results supported a synergistic effect of the combination (FICI \< 0.5, MIC of cefoperazone was set at 128 mg/L for the FICI calculation). However, the MICs of the combination and mono drugs were 128/64, \>128, and 128 mg/L for AB2092. The combination did not display a synergistic effect on AB2092.

###### 

The minimum inhibitory concentrations (MICs) of different antibiotics for AB1845 and AB2092.

  Antibiotics                  MIC (mg/L)    
  ---------------------------- ------------- ------------
  **Cefoperazone/sulbactam**   **16/8^∗^**   **128/64**
  Cefoperazone                 \>128         \>128
  Sulbactam                    32            128
  **Meropenem**                **16**        **64**
  **Imipenem**                 **16**        **64**
  **Doripenem**                **32**        **128**
  Colistin                     2             2
  Polymyxin B                  1             1
                                             

∗

FICI = 0.375; FICI = MIC

\(A\)

/MIC

(A in combination)

\+ MIC

\(B\)

/MIC

(B in combination)

. The bold values showed the increasing MIC of AB1845 compared with AB2092.

Interestingly, AB1845 and AB2092 also developed meropenem resistance with MIC increased from 16 to 64 mg/L, although the bacteria only exposed to meropenem for a short term (0.5 g every 8 h for 4 days). The isolates also developed resistance to imipenem and doripenem. Since both cefoperazone and meropenem are β-lactam antibiotics, the increased MIC in both cefoperazone/sulbactam and carbapenems may imply the similar underlying resistance mechanism. The isolates were only sensitive to colistin and polymyxin B, indicating an alternative choice for the AB2092 treatment. The MICs of the antibiotics are shown in **Table [1](#T1){ref-type="table"}**.

Pharmacokinetics and Pharmacodynamics (PK/PD)
---------------------------------------------

Plasma concentrations of cefoperazone and sulbactam at steady state were determined using the validated LC-MS/MS method, and the data were fitted into a developed population PK model (**Figure [1](#F1){ref-type="fig"}**). The pharmacokinetic parameters of cefoperazone and sulbactam are summarized in **Table [2](#T2){ref-type="table"}**. The T~1/2~ of cefoperazone was 4.1 h, which was a bit longer than the reported 1.8 h ([@B44]). This could attribute to liver dysfunction ([@B6]) according to the medical records of the patients. The T~1/2~ of sulbactam was 1.3 h, which was comparable to the published data ([@B44]).

![**The pharmacokinetic profiles of cefoperazone **(A)** and sulbactam **(B)**.** The dots in **(A,B)** are the concentration determined by LC-MS/MS (before the first infusion on Day 4 and 0.5, 1, 2, 4, 6 h after the infusion), and the curves are the profiles fitted to the population pharmacokinetic model. The red lines were indicated the concentration for the MIC of AB1845.](fmicb-07-01268-g001){#F1}

Pharmacokinetic/pharmacodynamic indices were calculated to evaluate the drug dosage regimen. The %T~\>MIC~ was the most predictive PK/PD index for cefoperazone and sulbactam ([@B13]; [@B52]), and the MIC of the combination was used for the %T~\>MIC~ calculation. In this study, the %T~\>MIC~ was 100% for cefoperazone and 34.5% for sulbactam for AB1845; and the %T~\>MIC~ was 0% for both cefoperazone and sulbactam for AB2092.

###### 

Pharmacokinetic parameters of cefoperazone and sulbactam.

  Parameters   Units    Cefoperazone   Sulbactam
  ------------ -------- -------------- -----------
  *T*~1/2~     h        4.1            1.3
  *T*~max~     h        1.4            1.3
  *C*~max~     mg/L     129.6          37.2
  AUC~0-8~     mg h/L   529.1          66.5
  AUC~0-inf~   mg h/L   766.0          68.3
  Vd           L        15.5           26.6
  CLt          L/h      2.6            14.6
  MRT~0-8~     h        2.6            1.5
  MRT~0-inf~   h        5.7            1.6
                                       

Whole-Genome Sequencing of AB1845 and AB2092
--------------------------------------------

The two isolates were initially typed by PFGE of *ApaI*-digested genomic DNA and shown to be the same strain. Whole-genome sequencing produced 12,050,346 and 12,191,576 pairs of 150-bp reads for AB1845 and AB2092, respectively. Assembly of the AB1845 and AB2092 genomes resulted in 132 and 131 contigs larger than 500 bp, comprising 4.0 megabases of sequence and representing a median 930-fold coverage. The AB1845 draft assembly has been deposited in GenBank (accession number LVYA00000000), and raw sequence reads for AB1845 and AB2092 have been submitted to NCBI's Sequence Read Archive under the study accession number SRP072783.

Automated gene prediction detected 3,811 and 3,810 putative coding sequences (CDSs) for AB1845 and AB2092, respectively. A phylogenetic tree was constructed, and the genome similarity was compared (**Figure [2](#F2){ref-type="fig"}**). The 3,718 CDSs were homologous (defined as a BLASTN *e*-value ≤ 1e^-10^) to the genome of *A. baumannii* MDR-ZJ06, which was a multi-drug-resistant isolate belonging to International clone II and wide spreading in China ([@B61]). MDR-ZJ06 was used as a reference genome for annotating genes in AB1845 and AB2092 (**Figure [3](#F3){ref-type="fig"}**). The results showed that the two isolates possess 97.6% similarity to MDR-ZJ06, with 921 and 915 SNPs, respectively. Certain genes were missing in both AB1845 and AB2092 compared with MDR-ZJ06. For example, 17 genes had a 15-kb fragment that was missing in the resistant island *Aba*R22, which includes transposition helper proteins, site-specific tyrosine recombinase, transposase protein A and conserved hypothetical proteins, among others.

![**Phylogenetic tree of AB1845 and AB2092 with 16 complete genomes of *A. baumannii* isolates in <ftp://ftp.ncbi.nlm.nih.gov/genomes/archive/old_genbank/>**.](fmicb-07-01268-g002){#F2}

![**Atlas of the *A. baumannii* AB1845 draft genome.** Each concentric circle represents the genomic data for AB1845. The two outer circles illustrate the predicted coding sequences on the plus and minus strands, respectively, colored by functional categories according to the COG classification. The third circle represents the location of the nucleotide substitution between AB1845 and AB2092, with blue representing genes affected by synonymous Single Nucleotide Polymorphisms (SNPs) and red representing SNPs in the intergenic region. The fourth circle displays the loci of the β-lactamase genes (pink) and genes around *bla*~OXA-23~ (gray). The fifth circle shows the GC content, and the 6th circle (innermost) represents GC skew (G--C)/(G+C) calculated using a 1-kb window.](fmicb-07-01268-g003){#F3}

The CDS of AB1845 was also mapped to the published plasmid sequence. It showed that certain AB1845 genes mapped to plasmid ABKp1 from the *A. baumannii* 1656-2 plasmid with 97.6% similarity.

A comparison of the CDS of AB1845 and AB2092 revealed only 33 SNPs. All of these SNPs were synonymous, indicating that SNP was not the main reason for the development of resistance (**Supplementary Table [S1](#SM1){ref-type="supplementary-material"}**).

β-Lactamase and Gene Amplification
----------------------------------

A well-known resistance enzyme for β-lactam antibiotics is β-lactamase. The class A, C, and D classes (*bla*~OXA-23~ and *bla*~OXA-51~) β-lactamase were identified in both AB1845 and AB2092 (**Supplementary Table [S2](#SM2){ref-type="supplementary-material"}**).

Gene amplification was detected by whole-genome sequencing in combination with the read depth method ([@B9]). Approximately 99.9% of the genes had a coverage ratio of AB2092 to AB1845 of approximately 1.0, but six genes (out of 3871 genes) had a coverage ratio over 3.0 (**Supplementary Table [S3](#SM3){ref-type="supplementary-material"}**). These six genes were AAA ATPase, DEAD/DEAH box helicases, *bla*~OXA-23~, and three hypothetical genes. Among these genes, AAA ATPase and DEAD/DEAH box helicases are involved in the function of DNA replication, repair, transcription, and two uncharacterized genes ([@B26]; [@B24]). The *bla*~OXA-23~ was gene encoded class D β-lactamase and conferred resistance to carbapenems and cefoperazone ([@B39]; [@B8]). All six genes were located in a 6-kb sequence fragment in AB1845 designated as *Tn2009*. *Tn2009* was flanked by two *ISAba1* elements that contributed to the duplication of *Tn2009* in AB2902 ([@B31]). The amplified genes were transcribed in the same orientation (**Figure [4](#F4){ref-type="fig"}**).

![**The illustration of the 6-kb DNA fragment of *Tn2009* in AB1845 and AB2092.** The fragment was amplified three times in AB2092.](fmicb-07-01268-g004){#F4}

mRNA Level of *bla*~OXA-23~ in AB1845 and AB2092
------------------------------------------------

Quantitative real-time PCR was conducted to measure the mRNA levels of *bla*~OXA-23~ in AB1845 and AB2092. Both isolates were collected at the early log phase, and the qPCR results showed that the mRNA level of *bla*~OXA-23~ was five times higher in AB2092 than in AB1845 (**Figure [5](#F5){ref-type="fig"}**). This finding was consistent with the gene amplification results.

![**Quantitative real-time PCR results for *bla*~OXA-23~ in AB1845 and AB2092 (^∗^student *t*-test *p* \< 0.05)**.](fmicb-07-01268-g005){#F5}

Discussion
==========

*Acinetobacter baumannii* commonly colonizes in respiratory tract of the hospitalized patients ([@B40]). It is difficult to characterize *A. baumannii* isolated from sputum belongs to the upper airway colonization or the causative pathogen of pneumonia. In this study, the two isolates were considered causative pathogens, as verified by pneumonia testing and symptoms such as cough, fever, and high white blood cell counts. To examine the mechanism of resistance development during cefoperazone/sulbactam treatment, both PK/PD indices and genomic sequencing were employed to understand the problem from a PK/PD and molecular perspective.

Exposure to a sub-optimal antibiotic concentration is the most important factor in the development of bacterial resistance. To optimize the antibiotic dosage regimen and prevent resistance, the PK/PD which bridges drug exposure and effect, has been widely applied in the clinics ([@B1]; [@B4]; [@B35]). To date, the PK/PD helps adjust dosage based on the evaluation of steady-state drug concentrations ([@B33]). In this study, blood samples were collected at steady state, and the MIC of the bacteria was determined. As the most predictive PK/PD index, the %T~\>MIC~ of cefoperazone and sulbactam was calculated and compared with published PK/PD targets. The published target %T~\>MIC~ of β-lactam antibiotics was 40--70% ([@B16]); however, there was no published target of sulbactam because of a lack of pharmacodynamic data. In our present dosage regimen (3 g q8h, infusion for 1 h), the target was 100% of cefoperazone and 34.5% of sulbactam for AB1845. Cefoperazone clearly reached its target, whereas there were no criteria for sulbactam. In a study of PK/PD simulation for sulbactam in healthy volunteers, in order for *A. baumannii* with an MIC of 8 mg/L to achieve the target of 40%, the sulbactam had to be administered as a 4-h infusion of 3 g q8h ([@B25]). It has even been suggested that the daily dose of sulbactam can be administered up to 6 g for *A. baumannii* infection ([@B3]) to achieve enhanced efficacy. A comparison of these data revealed that sulbactam should be administered at a much higher dose or prolonged infusion time. A suboptimal dose of sulbactam could lead to the development of resistance during treatment. Additional research to identify the PK/PD target of sulbactam specific to *Acinetobacter* is needed.

Whole-genome sequencing was further employed to investigate the mechanism of resistance from a molecular perspective. Comparison of the genome between AB1845 and AB2092 revealed no gene deletions or mutations (only 33 synonymous SNPs). However, the reads depth method showed six amplified genes on *Tn2009*, including *bla*~OXA-23~. The *bla*~OXA-23~ gene encodes the class D β-lactamase which confers resistance to the last resort carbapenem antibiotics. The OXA-23-producing *A. baumannii* is widely disseminated in multi-drug-resistant *A. baumannii*. Although the *bla*~OXA-23~ gene has been mainly identified on plasmids, its chromosomal location has also been reported ([@B61]). The transportable elements, *Tn2006*, *Tn2007*, *Tn2008*, and *Tn2009*, play a key role in the transfer of the *bla*~OXA-23~ gene to different locations in one bacterium or to different isolates ([@B14]; [@B31]). *Tn2008* and *Tn2009* have mostly been associated with the transfer of *bla*~OXA-23~ in China ([@B2]; [@B61]; [@B31]). IS elements are associated with the genome gain/loss of genes, especially resistant genes. These two transposons share IS*Aba1* upstream from *bla*~OXA-23~, which belongs to the IS4 family, provides promoter for *bla*~OXA-23~ ([@B53]; [@B36]), which could explain the gene duplication or amplification in this study. The mRNA level of *bla*~OXA-23~ confirmed the higher expression level of AB2092 and AB1845. There is evidence that gene duplication and amplification in bacteria was directly associated with adaptation to environmental changes, including antibiotic stress ([@B46]). In a study testing the relationships of gene amplification and β-lactams resistance increase showed that 70% colonies of *S. Typhimurium* with increased resistance to cephalosporin had increased *bla*~TEM~ gene copy numbers ([@B51]). Recent study showed the heteroresistance of *E. Coli* and *S. Typhimurium* was due to the amplification of *pmrD* gene which encoded a protein modifying lipid A. Moreover, the heteroresistance phenotype is associated with different copy numbers of the *pmrD* gene ([@B20]). Numerous studies have reported gene duplication and amplification related to bacterial resistance to antibiotics *in vitro* ([@B5]). During the macrolide treatment of a *Streptococcus pneumoniae* infection, the bacterium developed resistance due to an 18 bp duplication in the *rplV* gene, leading to the treatment failure. The duplication of *rplV* gene led to the blocking of macrolide binding site on ribosome ([@B37]). Another example of gene amplification in bacterial isolates from human patients involves the *Streptococcus agalactiae*, a leading cause of neonatal infection. The amplification of a four-fold tandemly amplified 13.5-kbp region and a 92 kbp duplication conferred drug resistance to both sulfonamide and trimethoprim ([@B7]).

In this study, the isolates developed resistance to cefoperazone/sulbactam as well as carbapenem antibiotics. The whole-genome sequencing showed the amplified *bla*~OXA-23~ in the isolates is very likely the contribution to the resistance. It is rational to conferred resistance to carbapenem antibiotics by the amplification of *bla*~OXA-23~. However, this is the first time to report the amplification of *bla*~OXA-23~ results in cefoperazone/sulbactam combination resistance. Further studies will be focused on collecting more clinical isolates pairs of *A. baumannii* to support the mechanism proposed.
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